Most common treatment-emergent adverse events after brentuximab vedotin therapy
| . | All grades (N = 25) . | Grade 3 or higher (N = 25) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Cough | 13 | 52 | ||
| Fatigue | 13 | 52 | 2 | 8 |
| Pyrexia | 13 | 52 | 2 | 8 |
| Nausea | 12 | 48 | 1 | 4 |
| Peripheral sensory neuropathy | 12 | 48 | 1 | 4 |
| Dyspnea | 10 | 40 | 1 | 4 |
| Diarrhea | 9 | 36 | ||
| Headache | 9 | 36 | ||
| Upper respiratory tract infection | 9 | 36 | ||
| Alopecia | 8 | 32 | ||
| Anemia | 7 | 28 | 5 | 20 |
| Back pain | 7 | 28 | 1 | 4 |
| Decreased appetite | 7 | 28 | 1 | 4 |
| Myalgia | 7 | 28 | ||
| Neutropenia | 7 | 28 | 6 | 24 |
| Oropharyngeal pain | 7 | 28 | ||
| Vomiting | 7 | 28 | ||
| Arthralgia | 6 | 24 | ||
| Chills | 6 | 24 | ||
| Pruritus | 6 | 24 | ||
| Constipation | 5 | 20 | 1 | 4 |
| Pleural effusion | 5 | 20 | 1 | 4 |
| Pneumonia | 5 | 20 | 2 | 8 |
| . | All grades (N = 25) . | Grade 3 or higher (N = 25) . | ||
|---|---|---|---|---|
| n . | % . | n . | % . | |
| Cough | 13 | 52 | ||
| Fatigue | 13 | 52 | 2 | 8 |
| Pyrexia | 13 | 52 | 2 | 8 |
| Nausea | 12 | 48 | 1 | 4 |
| Peripheral sensory neuropathy | 12 | 48 | 1 | 4 |
| Dyspnea | 10 | 40 | 1 | 4 |
| Diarrhea | 9 | 36 | ||
| Headache | 9 | 36 | ||
| Upper respiratory tract infection | 9 | 36 | ||
| Alopecia | 8 | 32 | ||
| Anemia | 7 | 28 | 5 | 20 |
| Back pain | 7 | 28 | 1 | 4 |
| Decreased appetite | 7 | 28 | 1 | 4 |
| Myalgia | 7 | 28 | ||
| Neutropenia | 7 | 28 | 6 | 24 |
| Oropharyngeal pain | 7 | 28 | ||
| Vomiting | 7 | 28 | ||
| Arthralgia | 6 | 24 | ||
| Chills | 6 | 24 | ||
| Pruritus | 6 | 24 | ||
| Constipation | 5 | 20 | 1 | 4 |
| Pleural effusion | 5 | 20 | 1 | 4 |
| Pneumonia | 5 | 20 | 2 | 8 |
Includes adverse events of any relationship occurring in at least 20% of patients.